Serum levels of polychlorinated biphenyls and risk of non-Hodgkin lymphoma: A hospital-based case-control study.


Journal

Chemosphere
ISSN: 1879-1298
Titre abrégé: Chemosphere
Pays: England
ID NLM: 0320657

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 16 04 2019
revised: 06 06 2019
accepted: 25 06 2019
entrez: 29 9 2019
pubmed: 29 9 2019
medline: 28 11 2019
Statut: ppublish

Résumé

Polychlorinated biphenyls (PCB) have been classified by the International Agency for Research on Cancer (IARC) in Group 1 as carcinogenic to human, based on sufficient evidence in humans of an increased risk of cutaneous malignant melanoma and limited evidence for non-Hodgkin lymphoma (NHL). However present findings on the association of PCB exposure and NHL are still controversial. This study examined the relationship between PCB serum levels and risk of NHL in a Northern Italy area (Brescia province), where a chemical factory produced PCBs from 1938 to 1984, causing human contamination. A case-control study of 215 NHL patients and 215 control subjects was conducted. Cases and controls were assayed for serum levels of 33 PCB congeners. No associations were found between risk of NHL and serum levels of total PCBs (OR = 0.51; 95% CI: 0.25-1.04 for highest vs lowest quartile) or specific PCB congeners. The study confirmed a strong association of NHL with HCV infection (OR = 3.60; 95% CI: 1.30-10.02). This case-control study does not support the hypothesis of an association between current serum levels of PCBs and NHL development in the general population.

Identifiants

pubmed: 31561313
pii: S0045-6535(19)31434-1
doi: 10.1016/j.chemosphere.2019.06.193
pii:
doi:

Substances chimiques

Air Pollutants, Occupational 0
Polychlorinated Biphenyls DFC2HB4I0K

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

969-975

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Michele Magoni (M)

ATS Brescia (Brescia Health Protection Agency), Brescia, Italy. Electronic address: michele.magoni@ats-brescia.it.

Francesco Donato (F)

Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Unit of Hygiene, Epidemiology, and Public Health, University of Brescia, Italy.

Pietro Apostoli (P)

Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Institute of Occupational Health and Industrial Hygiene, University of Brescia, Italy.

Giuseppe Rossi (G)

Division of Haematology, Department of Clinical Oncology, ASST Spedali Civili, Brescia, Italy.

Pietro Comba (P)

Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Lucia Fazzo (L)

Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Fabrizio Speziani (F)

ATS Brescia (Brescia Health Protection Agency), Brescia, Italy.

Lucia Leonardi (L)

ATS Brescia (Brescia Health Protection Agency), Brescia, Italy.

Grazia Orizio (G)

ATS Brescia (Brescia Health Protection Agency), Brescia, Italy.

Carmelo Scarcella (C)

ATS Brescia (Brescia Health Protection Agency), Brescia, Italy.

Antonella Anastasia (A)

Division of Haematology, Department of Clinical Oncology, ASST Spedali Civili, Brescia, Italy.

Alessandra Tucci (A)

Division of Haematology, Department of Clinical Oncology, ASST Spedali Civili, Brescia, Italy.
Members of the Brescia NHL-PCB Working Group: Carmen Terraroli (Chief for coordination and clinical Research, ASST Spedali Civili), Arianna Coniglio (Surgical Clinic, Department of Experimental and Clinical Sciences, University of Brescia - Division of General Surgery, Brescia Hospital), Guido Zarattini (Orthopaedic Clinic University of Brescia, II Division of Orthopaedic and Traumatology Spedali Civili of Brescia, Italy), Giorgio Manca (Department of Plastic Surgery, ASST Spedali Civili, Brescia, Italy), Jacopo Fostinelli (Department of Medical and Surgical Specialties Radiological Sciences and Public Health, Institute of Occupational Health and Industrial Hygiene, University of Brescia), Roberto Festa, Maria Conti, Stefania Micheletti (Brescia Health Protection Agency), Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH